COPPADIS‐2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation. (4th July 2019)

• Record Type: Journal Article
• Authors: Santos García, D.; Jesús, S.; Aguilar, M.; Planellas, L. L.; García Caldentey, J.; Caballol, N.; Legarda, I.; Hernández Vara, J.; Cabo, I.; López Manzanares, L.; González Aramburu, I.; Ávila Rivera, M. A.; Catalán, M. J.; López Díaz, L.; Puente, V.; García Moreno, J. M.; Borrué, C.; Solano Vila, B.; Álvarez Sauco, M.; Vela, L.; Escalante, S.; Cubo, E.; Carrillo Padilla, F.; Martínez Castrillo, J. C.; Sánchez Alonso, P.; Alonso Losada, M. G.; López Ariztegui, N.; Gastón, I.; Kulisevsky, J.; Menéndez González, M.; Seijo, M.; Rúiz Martínez, J.; Valero, C.; Kurtis, M.; de Fábregues‐Boixar, O.; González Ardura, J.; Prieto Jurczynska, C.; Martinez‐Martin, P.; Mir, P.;
• Other Names: Adarmes Astrid D. investigator.; Almeria M. investigator.; Alonso Cánovas A. investigator.; Alonso Frech F. investigator.; Aneiros Díaz A. investigator.; Arnáiz S. investigator.; Arribas S. investigator.; Ascunce Vidondo A. investigator.; Bernardo Lambrich N. investigator.; Bejr‐Kasem H. investigator.; Blázquez Estrada M. investigator.; Botí M. investigator.; Cabello González C. investigator.; Cámara Lorenzo A. investigator.; Carrillo F. investigator.; Casas E. investigator.; Clavero P. investigator.; Cortina Fernández A. investigator.; Cots Foraster A. investigator.; Crespo Cuevas A. investigator.; de Deus Fonticoba T. investigator.; Díez‐Fairen M. investigator.; Erro E. investigator.; Estelrich Peyret E. investigator.; Fernández Guillán N. investigator.; Gámez P. investigator.; Gallego M. investigator.; García Campos C. investigator.; Gómez Garre M. P. investigator.; González Aloy J. investigator.; González García B. investigator.; González Palmás M. J. investigator.; González Toledo G. R. investigator.; Golpe Díaz A. investigator.; Grau Solá M. investigator.; Guardia G. investigator.; Horta‐Barba A. investigator.; Infante J. investigator.; Labandeira C. investigator.; Labrador M. A. investigator.; Lacruz F. investigator.; Lage Castro M. investigator.; López Seoane B. investigator.; Macías Y. investigator.; Mata M. investigator.; Martí Andres G. investigator.; Martí M. J. investigator.; McAfee D. investigator.; Meitín M. T. investigator.; Méndez del Barrio C. investigator.; Miranda Santiago J. investigator.; Morales Casado M. I. investigator.; Moreno Diéguez A. investigator.; Nogueira V. investigator.; Novo Amado A. investigator.; Novo Ponte S. investigator.; Ordás C. investigator.; Pagonabarraga J. investigator.; Pareés I. investigator.; Pascual‐Sedano B. investigator.; Pastor P. investigator.; Pérez Fuertes A. investigator.; Pérez Noguera R. investigator.; Prats M. A. investigator.; Pueyo Morlans M. investigator.; Redondo Rafales N. investigator.; Rodríguez Méndez L. investigator.; Rodríguez Pérez A. B. investigator.; Roldán F. investigator.; Ruíz De Arcos M. investigator.; Sánchez‐Carpintero M. investigator.; Sánchez Díez G. investigator.; Sánchez Rodríguez A. investigator.; Santacruz P. investigator.; Segundo Rodríguez J. C. investigator.; Serarols A. investigator.; Sierra Peña M. investigator.; Suárez Castro E. investigator.; Tartari J. P. investigator.; Vargas L. investigator.; Vázquez Gómez R. investigator.; Villanueva C. investigator.; Vives B. investigator.; Villar M. D. investigator.;
• Is Part Of: European journal of neurology. Volume 26:Number 11(2019)
• Page Start: 1399
• Page End: 1407
• Publication Date: 2019-07-04
• Subjects: gait -- mood -- motor fluctuations -- non‐motor symptoms -- Parkinson's disease -- quality of life; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.14008
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well‐designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS‐2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). Methods: This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. Results: In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non‐Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non‐motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Conclusions: Parkinson's disease is a complex disorder and different non‐motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.